He directs investors to an article in the New Yorker that explains how the company has a novel way of killing cancer in a targeted way by attacking the metabolism of cancer rather than carpet bombing the area. He says it is a unique company and points to positive results from Tuesday night that showed "out-and-out remission" of leukemia.
Cramer says he continues to believe Celgene (CELG - Get Report) will buy this $3 billion company if it continues to perform as well as it has, even though he knows the CEO has a desire to build his own franchise. But Cramer says investors win either way. He thinks Agios is still not expensive if this drug works, and it appears to be working now.AGIO data by YCharts